Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam, Merck, Sirna, Sigma-Aldrich

Premium
Alnylam Expects to Raise $101M in Stock Offering
 
Alnylam Pharmaceuticals this week said that it is publicly offering 4.7 million shares of its common stock.
 
The underwriter of the offering, Banc of America Securities, has also been granted a 30-day option to buy an additional 705,000 shares, Alnylam said.
 
The RNAi drug developer said it expects net proceeds of the offering to be approximately $101 million.
 

 
Waiting Period on Merck, Sirna Acquisition Expires
 
The federal regulatory antitrust waiting period for Merck’s proposed $1.1 billion acquisition of Sirna Therapeutics has expired, the companies said this week.
 
Merck announced its plan to buy Sirna for $13 a share in cash in late October (see RNAi News, 11/2/2006).
 
Consummation of the acquisition, which is expected to occur before the end of this year or early in the first quarter of 2007, remains subject to other customary closing conditions, including the approval of the merger by holders of Sirna's common stock and the absence of a material adverse effect on Sirna since the signing of the merger agreement, the companies said.
 
Sirna shareholders are scheduled to vote on the transaction on Dec. 28. Sirna has said that investors holding 36 percent of the company’s equity have committed to supporting the deal.
 

 
Sigma-Aldrich Amends Terms of Credit Facility, Closes $100M Debt
 
Sigma-Aldrich this week said it has amended the terms of a $150 million credit facility it established in February 2005.
 
Sigma exercised the facility’s $150 million accordion feature, making the new one a five-year, $300 million facility that matures on Dec. 11, 2011.
 
The company said the revision will bolster liquidity for its commercial paper, or short-term debt, program, and for general purposes.
 
Last week, Sigma-Aldrich said that it closed a $100 million in debt offering by selling 5.1-percent senior notes due Dec. 5, 2011, to a private investor.
 

The company said it retired $75 million 5.2 percent senior notes that matured on Nov. 20.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.